PhaseBio Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Recent Business Highlights
30 mars 2020 08h01 HE
|
PhaseBio Pharmaceuticals, Inc.
Recently Initiated PB2452 Phase 3 Trial for the Reversal of the Antiplatelet Effects of Ticagrelor Received FDA Breakthrough Therapy Designation and EMA PRIME Designation for PB2452 Secured PB2452...
PhaseBio to Present at Cowen and Company 40th Annual Health Care Conference
26 févr. 2020 16h01 HE
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa. and SAN DIEGO, Feb. 26, 2020 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...
PhaseBio Appoints Alex C. Sapir to Board of Directors
13 févr. 2020 16h01 HE
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa. and SAN DIEGO, Feb. 13, 2020 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...
PhaseBio Announces European Regulatory Update for PB2452
11 févr. 2020 08h00 HE
|
PhaseBio Pharmaceuticals, Inc.
PB2452 granted PRIME Designation by the European Medicines Agency PhaseBio receives written scientific advice confirming PB2452 clinical development plan In Phase 1 and Phase 2a clinical trials,...
PhaseBio Announces Case Study Highlighting PB1046 Hemodynamic Data Presented at the 14th Pulmonary Vascular Research Institute World Congress
04 févr. 2020 16h01 HE
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa. and SAN DIEGO, Calif., Feb. 04, 2020 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...
PhaseBio Announces Acquisition of Novel Oral Aldosterone Synthase Inhibitor to Develop for Treatment-Resistant Hypertension
13 janv. 2020 16h01 HE
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa. and SAN DIEGO, Jan. 13, 2020 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...
PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals® for PB2452
10 janv. 2020 09h00 HE
|
PhaseBio Pharmaceuticals, Inc.
PhaseBio to receive up to $120 million in development funding PhaseBio retains exclusive worldwide commercial rights to PB2452 MALVERN, Pa. and SAN DIEGO, Jan. 10, 2020 (GLOBE NEWSWIRE) --...
PhaseBio to Present at Stifel 2019 Healthcare Conference
15 nov. 2019 08h00 HE
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa. and SAN DIEGO, Calif., Nov. 15, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...
PhaseBio Reports Third Quarter 2019 Financial Results and Recent Corporate Progress
14 nov. 2019 08h00 HE
|
PhaseBio Pharmaceuticals, Inc.
Received Written End-of-Phase 1 Meeting Minutes Outlining Clear Development Path for PB2452 Completed Phase 2a Trial of PB2452 in Older and Elderly Subjects on Dual Antiplatelet Therapy Initiated...
PhaseBio To Report Third Quarter 2019 Financial Results and Recent Corporate Progress on November 14, 2019
07 nov. 2019 16h01 HE
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa. and SAN DIEGO, Nov. 07, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...